Disease Prevalence & Burden

Disease Prevalence & Burden

Prevalence, incidence, patient counts, mortality rates, and socioeconomic burden across neurodegenerative diseases.

Overview

Neurodegenerative diseases represent a growing global health crisis, with over 55 million people living with dementia alone and millions more affected by [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other progressive neurological conditions[^1]. NeuroWiki currently contains 337 individual disease entries covering the full spectrum of neurodegenerative conditions, from common diseases like Alzheimer's and Parkinson's to rare genetic disorders.

The collective burden of these diseases extends far beyond the individuals affected, impacting families, caregivers, healthcare systems, and economies worldwide. Understanding prevalence patterns is essential for healthcare planning, resource allocation, and research prioritization.

Major Neurodegenerative Diseases

The following table summarizes the most prevalent neurodegenerative diseases worldwide:

Disease Prevalence & Burden

Prevalence, incidence, patient counts, mortality rates, and socioeconomic burden across neurodegenerative diseases.

Overview

Neurodegenerative diseases represent a growing global health crisis, with over 55 million people living with dementia alone and millions more affected by [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other progressive neurological conditions[^1]. NeuroWiki currently contains 337 individual disease entries covering the full spectrum of neurodegenerative conditions, from common diseases like Alzheimer's and Parkinson's to rare genetic disorders.

The collective burden of these diseases extends far beyond the individuals affected, impacting families, caregivers, healthcare systems, and economies worldwide. Understanding prevalence patterns is essential for healthcare planning, resource allocation, and research prioritization.

Major Neurodegenerative Diseases

The following table summarizes the most prevalent neurodegenerative diseases worldwide:

| Disease | Estimated Global Prevalence | Key Risk Factors |
|---------|------------------------------|------------------|
| [Alzheimer's Disease](/diseases/alzheimers-disease) | ~55 million people | Age, [APOE](/proteins/apoe) ε4, family history |
| [Parkinson's Disease](/diseases/parkinsons-disease) | ~10 million people | Age, genetic ([LRRK2](/entities/lrrk2), GBA), environmental |
| [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) | ~500,000 people | Age, [C9orf72](/entities/c9orf72), SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy) |
| [Frontotemporal Dementia](/diseases/frontotemporal-dementia) | ~3 million people | GRN, [MAPT](/proteins/tau), C9orf72 mutations |
| [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) | ~5 million people | Age, [α-synuclein](/proteins/alpha-synuclein) pathology |
| [Huntington Disease](/diseases/huntington-disease) | ~1 million people | [HTT](/proteins/huntingtin) gene expansion (CAG repeat) |

Alzheimer's Disease

[Alzheimer's disease](/diseases/alzheimers-disease) is the most common cause of dementia, accounting for 60-70% of all cases worldwide[^1]. The disease is characterized by progressive memory loss, cognitive decline, and behavioral changes.

Epidemiology:

• Global prevalence: 55 million people (2023)
• Annual new cases: ~10 million
• Projected prevalence by 2050: 139 million (without disease-modifying treatments)
• Age-specific prevalence doubles every 5 years after age 65
• Women are disproportionately affected (approximately 2/3 of cases)

• Ages 65-74: ~1-3% annual incidence
• Ages 75-84: ~5-10% annual incidence
• Ages 85+: ~15-20% annual incidence

• Alzheimer's is the 6th leading cause of death in the United States
• Average survival after diagnosis: 4-8 years (can range from 3-20 years)

Parkinson's Disease

[Parkinson's disease](/diseases/parkinsons-disease) is the second most common neurodegenerative disorder, characterized by motor symptoms including tremor, bradykinesia, rigidity, and postural instability[^2].

Epidemiology:

• Global prevalence: ~10 million people
• Prevalence increases sharply with age: <1% at age 50, 1-3% at age 70, 3-5% at age 80+
• Approximately 1 million people in the United States
• Men are 1.5x more likely to develop PD than women

• Annual incidence: ~60-120 per 100,000 in developed countries
• Approximately 60,000 new diagnoses annually in the US

• Survival 5-15 years after diagnosis is typical
• Mortality is usually due to falls, pneumonia, or complications of advanced disease

Amyotrophic Lateral Sclerosis

[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS) is a fatal motor neuron disease characterized by progressive muscle weakness and paralysis[^3].

Epidemiology:

• Global prevalence: ~500,000 people
• Prevalence has increased 4-fold over the past 3 decades
• Peak onset age: 55-65 years
• Slight male predominance (1.2-1.5:1)

• Annual incidence: 1-2 per 100,000
• Approximately 5,000 new diagnoses annually in the US

• Median survival: 2-5 years from symptom onset
• 10% survive >5 years (including Stephen Hawking)
• Riluzole and edaravone modestly extend survival

Frontotemporal Dementia

[Frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD) encompasses a group of disorders characterized by progressive degeneration of the frontal and temporal lobes[^4].

Epidemiology:

• Global prevalence: ~3 million people
• Accounts for 10-20% of all dementias
• Peak onset age: 45-65 years (earlier than AD)
• Equal gender distribution

• Annual incidence: 1-2 per 100,000 in ages 45-64

Huntington Disease

[Huntington disease](/diseases/huntington-disease) is an autosomal dominant disorder caused by CAG repeat expansion in the [HTT](/proteins/huntingtin) gene[^5].

Epidemiology:

• Global prevalence: ~1 million people
• Higher prevalence in populations of European descent (~10-15 per 100,000)
• Lower prevalence in Asian and African populations (~0.5 per 100,000)

• CAG repeat >35: penetrant allele
• Repeat length correlates with earlier onset
• Juvenile-onset HD: paternal transmission, >60 repeats

Rare Neurodegenerative Disorders

NeuroWiki includes extensive coverage of rare neurodegenerative conditions. These disorders, while individually uncommon, collectively affect significant patient populations and provide important insights into disease mechanisms.

Tauopathies

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy) — Tauopathy with vertical gaze palsy, affecting ~6 per 100,000
• [Corticobasal Degeneration (CBD](/diseases/corticobasal-degeneration) — Asymmetric rigidity and apraxia, affecting ~5 per 100,000
• [Primary Age-Related Tauopathy (PART)] — Aging-related tau pathology without amyloid
• [Chronic Traumatic Encephalopathy (CTE)] — Tauopathy secondary to repetitive brain trauma

α-Synucleinopathies

• [Multiple System Atrophy (MSA](/diseases/multiple-system-atrophy) — α-synucleinopathy with autonomic failure, affecting ~4 per 100,000
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) — Second most common dementia
• [Parkinson's Disease with Dementia](/diseases/parkinsons-disease) — PD progressing to dementia

Other Rare Disorders

• [Normal Pressure Hydrocephalus](/diseases/normal-pressure-hydrocephalus) — Treatable dementia triad
• [Posterior Cortical Atrophy](/diseases/posterior-cortical-atrophy) — Visual dementia variant
• [Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob-disease) — Prion disease
• [Wilson Disease](/diseases/wilson-disease) — Copper accumulation disorder
• [Pantothenate Kinase-Associated Neurodegeneration (PKAN](/diseases/pantothenate-kinase-associated-neurodegeneration-pkan) — Rare movement disorder

Disease Classification

Neurodegenerative diseases in the wiki are organized into several major categories:

By Protein Pathology

The classification of neurodegenerative diseases by their characteristic protein aggregates has become central to understanding disease mechanisms and developing targeted therapies:

• Tauopathies: [Alzheimer's disease](/diseases/alzheimers-disease), [PSP](/diseases/progressive-supranuclear-palsy), [CBD](/diseases/corticobasal-degeneration), PART
• α-Synucleinopathies: [Parkinson's disease](/diseases/parkinsons-disease), [DLB](/diseases/dementia-with-lewy-bodies), MSA
• TDP-43 Proteinopathies: [ALS](/diseases/amyotrophic-lateral-sclerosis), FTD, FTLD
• Polyglutamine Diseases: [Huntington's disease](/diseases/huntington-disease), spinocerebellar ataxias
• Prion Diseases: CJD, fatal insomnia, variably protease-sensitive prionopathy
• Transactive Response DNA-Binding Proteinopathies: ALS, FTD

By Clinical Syndrome

• [Dementias](/diseases) — Memory and cognitive impairment
• [Movement Disorders](/diseases/parkinsons-disease) — Motor system degeneration
• [Motor Neuron Diseases](/diseases/amyotrophic-lateral-sclerosis) — Upper/lower motor neuron loss
• [Ataxias](/diseases) — Cerebellar dysfunction
• [Extrapyramidal Disorders](/diseases) — Basal ganglia disorders

By Inheritance Pattern

• Autosomal Dominant: Huntington disease, familial AD (APP, PSEN1/2), FTD (GRN, MAPT, C9orf72), familial PD (LRRK2)
• Autosomal Recessive: Wilson disease, PKAN (PANK2), Ataxia-telangiectasia
• Mitochondrial: MELAS, MERRF
• Sporadic: Most cases of AD, PD, ALS

Burden Statistics

United States Estimates

| Disease | Patients (millions) | Annual Deaths | Leading Cause |
|---------|---------------------|---------------|---------------|
| Alzheimer's disease | 6.5 | 150,000 | 6th |
| Parkinson's disease | 1.0 | 40,000 | 14th |
| ALS | 0.03 | 5,000 | 3rd (ages 45-64) |
| All dementias | 6.0 | 200,000 | 5th |

Global Impact

• Over 55 million people worldwide live with dementia[^1]
• Parkinson's affects ~10 million globally[^2]
• ALS: ~500,000 people affected globally[^3]
• Neurodegenerative diseases are the 2nd leading cause of death globally
• Combined global cost: >$1.5 trillion annually

Prevalence by Region

Neurodegenerative disease prevalence varies geographically:

| Region | AD (millions) | PD (millions) | Notes |
|--------|---------------|---------------|-------|
| North America | 6.5 | 1.0 | Highest AD prevalence |
| Europe | 7.5 | 1.2 | High PD rates |
| Asia | 25.0 | 6.0 | Largest absolute numbers |
| Africa | 2.0 | 0.5 | Likely underdiagnosed |
| Latin America | 3.0 | 0.8 | Growing recognition |

Regional Variations:

• Japan: Highest longevity, leading to high AD prevalence
• India: Lower AD rates hypothesized to be protective factors
• Mediterranean regions: Lower rates attributed to diet (Mediterranean diet)
• Western Europe: High PD rates, possibly due to environmental factors

Age-Specific Patterns

• <40 years: Rare, primarily genetic forms (juvenile PD, early-onset AD, genetic ataxias)
• 40-65 years: Early-onset neurodegenerative diseases become more common
• 65-85 years: Prevalence doubles every 5 years
• >85 years: Plateau or slight decrease in incidence, may reflect survival bias

Risk Factors

Non-Modifiable Risk Factors

• Age: Primary risk factor for all neurodegenerative diseases[^1]
• Sex: Variable by disease; women >2x risk for AD, men higher for PD
• Genetics: [APOE ε4](/genes/apoe) for AD, [LRRK2](/genes/lrrk2) for PD, [C9orf72](/genes/c9orf72) for ALS/FTD
• Family History: 2-4x increased risk with first-degree relative
• Ethnicity: Variable patterns across populations

Potentially Modifiable Risk Factors

• Vascular factors: Hypertension, diabetes, stroke history[^6]
• Lifestyle: Smoking (mixed evidence), physical inactivity, poor diet
• Head Trauma: Repeated concussions increase CTE, PD, and AD risk
• Occupational Exposures: Pesticides, solvents, metals
• Sleep Disorders: REM sleep behavior disorder predicts α-synucleinopathies
• Depression: Associated with increased neurodegenerative disease risk

Protective Factors

• Education: Higher education associated with cognitive reserve
• Physical Activity: Regular exercise reduces AD and PD risk
• Mediterranean Diet: Associated with reduced cognitive decline
• Social Engagement: Cognitive and social stimulation
• Statins: Mixed evidence for potential protective effects

Economic Burden

Direct Medical Costs

• AD care costs: ~$345 billion annually (US)[^7]
• PD costs: ~$52 billion annually (US)[^8]
• ALS costs: ~$1.5 billion annually (US)
• All neurodegenerative diseases: >$500 billion annually (US)

Cost Components

| Category | AD | PD | ALS |
|----------|----|----|-----|
| Hospitalization | 30% | 25% | 20% |
| Nursing home care | 45% | 30% | 40% |
| Physician/Clinic | 10% | 20% | 15% |
| Medications | 5% | 15% | 10% |
| Other | 10% | 10% | 15% |

Indirect Costs

• Lost productivity: $100 billion+ annually
• Informal caregiving: Valued at $300+ billion annually
• Family caregiver burden: Physical, emotional, financial stress
• Premature mortality: Significant years of productive life lost

International Comparisons

• US: Highest per-patient costs due to healthcare system
• UK: NHS costs >£23 billion annually for dementia
• EU: Combined neurodegenerative disease costs >€300 billion
• Low/middle-income countries: Lower direct costs but less infrastructure

Demographic Trends

Global Aging Population

• Population aged 65+ will double by 2050 to 1.6 billion
• Oldest-old (85+) growing fastest, tripling by 2050
• Implications: Exponential increase in neurodegenerative disease prevalence
• Healthcare systems unprepared for projected increases

Geographic Shifts

• Developing countries: Rising prevalence as life expectancy increases
• China: Projected 10 million AD patients by 2050
• India: Rapidly aging population, underprepared healthcare
• Africa: Least prepared for neurodegenerative disease burden

Early-Onset Cases

• Growing recognition of presentations before age 65
• 5-10% of AD cases are early-onset (<65)
• 10-15% of PD cases are early-onset (<50)
• Genetic forms account for higher proportion of early-onset cases

Gender Considerations

• Women bear disproportionate caregiving burden
• Female caregivers report higher stress and health impacts
• Women are 2x more likely to develop AD
• Men slightly more likely to develop PD

Research and Policy Implications

Healthcare Planning

• Need for specialized care facilities
• Training requirements for healthcare workforce
• Long-term care infrastructure needs
• Palliative care integration

Research Priorities

• Disease-modifying therapies
• Early detection and biomarkers
• Risk reduction strategies
• Caregiver support interventions

Policy Needs

• Increased research funding
• Access to diagnostic tools and treatments
• Caregiver support policies
• Healthcare system adaptation

Key Publications

[^1]: [GBD 2019 Dementia Forecasting Collaborators, Lancet Neurology 2020](https://pubmed.ncbi.nlm.nih.gov/32087858/). Projection of dementia prevalence.

[^2]: [Parkinson's Foundation, 2023](https://www.parkinson.org/Understanding/Statistics). Parkinson's disease prevalence statistics.

[^3]: [Hardiman et al., Nature Reviews Neurology 2016](https://pubmed.ncbi.nlm.nih.gov/27786256/). Amyotrophic lateral sclerosis epidemiology.

[^4]: [Rascovsky et al., Brain 2011](https://pubmed.ncbi.nlm.nih.gov/21908734/). Clinical features of frontotemporal dementia.

[^5]: [The Huntington's Disease Collaborative Research Project, Cell 1993](https://pubmed.ncbi.nlm.nih.gov/8102241/). Identification of Huntington disease gene.

[^6]: [Kivipelto et al., Lancet Neurology 2018](https://pubmed.ncbi.nlm.nih.gov/29526591/). Vascular risk factors for dementia.

[^7]: [Alzheimer's Association, 2023](https://www.alz.org/alzheimers-dementia/facts-figures). Alzheimer's disease economic burden.

[^8]: [Parkinson's Foundation, 2022](https://www.parkinson.org/Understanding/Statistics). Economic impact of Parkinson's disease.

See Also

• [Disease Classification & Relationships](/disease-classification-&-relationships)
• [Disease Progression & Staging](/disease-progression-&-staging)
• [Treatment Pipeline Overview](/treatment-pipeline-overview)
• [Mechanism Categories](/mechanisms/_mechanism-categories)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

Data Sources

Prevalence estimates derived from peer-reviewed epidemiological studies and global burden of disease reports[^1][^2][^3]. See individual disease pages for specific references. This page is auto-maintained. Last updated: 2026-03-26

External Links

• [World Health Organization - Dementia](https://www.who.int/health-topics/dementia)
• [Parkinson's Foundation Statistics](https://www.parkinson.org/Understanding/Statistics)
• [Alzheimer's Association Facts and Figures](https://www.alz.org/alzheimers-dementia/facts-figures)
• [GBD 2019 Database](https://vizhub.healthdata.org/gbd/)

References